Panbela Therapeutics, Inc. Common Stock
PBLA
PBLA was delisted on the 6th of March, 2024.
7 hedge funds and large institutions have $111K invested in Panbela Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 6 closing their positions.
30% less funds holding
Funds holding: 10 → 7 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
94% less capital invested
Capital invested by funds: $1.78M → $111K (-$1.67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
+$37K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$37K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$750K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$482K |
| 3 |
FPS
Fieldpoint Private Securities
Greenwich,
Connecticut
|
-$132K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$72K |
| 5 |
BlackRock
New York
|
-$61K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BAMG
1
Brand Asset Management Group
Chesterfield,
Missouri
| $38K | – | – | – |
|
|
BSW
2
Buckingham Strategic Wealth
Clayton,
Missouri
| $16K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $12K | +$37K | +1 | New |
|
|
E
4
Ergoteles
New York
| $11K | +$37K | +1 | New |
|
5
Geode Capital Management
Boston,
Massachusetts
| $9K | – | – | – |
|
6
Morgan Stanley
New York
| $8K | – | – | – |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $8K | +$37K | +1 | New |
|
8
Citadel Advisors
Miami,
Florida
| $7K | – | – | – |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $2K | – | – | – |
|
|
IC
10
Ikarian Capital
Dallas,
Texas
| – | -$750K | -15 | Closed |
|
|
11
Vanguard Group
Malvern,
Pennsylvania
| – | -$482K | -10 | Closed |
|
|
FPS
12
Fieldpoint Private Securities
Greenwich,
Connecticut
| – | -$132K | -3 | Closed |
|
|
13
BlackRock
New York
| – | -$61K | -1 | Closed |
|
|
BFM
14
Boothbay Fund Management
New York
| – | -$72K | -1 | Closed |
|
15
Verition Fund Management
Greenwich,
Connecticut
| – | -$42K | -1 | Closed |
|
PBLA Hedge Fund Activity: Q2 2022 in Review
7 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q2 2022, worth a combined $111K — down 94% from $1.78M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PBLA and 3 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Ergoteles, opening a new position worth an estimated $37K. The largest seller was Ikarian Capital, exiting entirely with an estimated $750K sold.
- 7 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q2 2022, down from 10 in Q1 2022.
- Funds reported $111K of Panbela Therapeutics, Inc. Common Stock stock for Q2 2022, down 94% quarter-over-quarter.
- 3 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q2 2022 and 6 closed out, a net change of -3 holders.
- The largest Panbela Therapeutics, Inc. Common Stock buyer in Q2 2022 was Ergoteles, an estimated $37K added.
- The largest Panbela Therapeutics, Inc. Common Stock seller in Q2 2022 was Ikarian Capital, an estimated $750K sold.
Based on aggregated 13F filings for Q2 2022.